Dr. Marc Siegel, a senior medical analyst, discussed a study from the University of California San Diego on ‘Fox & Friends.’ The study examined the impact of GLP-1 weight loss medications on aging. Siegel highlighted potential cardiovascular and neurological benefits, while also noting digestive and thyroid-related side effects.
Researchers are investigating a rare but severe brain condition, Wernicke encephalopathy, which could be linked to GLP-1 medications. Published in Clinical Nutrition, the study found 15 cases of this neurological disorder, associated with severe vitamin B1 deficiency, in patients using GLP-1 receptor agonists.
The cases mainly involved semaglutide (brands: Ozempic, Wegovy) and tirzepatide (brands: Mounjaro, Zepbound). Most patients experienced weight loss, vomiting, loss of appetite, or malnutrition.
The study identified cases through the FDA’s Adverse Event Reporting System and medical literature. Researchers emphasized that the study cannot confirm these medications as the cause of the condition.
Vitamin B1 is critical for brain health. Deficiencies may lead to confusion, difficulty walking, balance problems, and vision changes. Untreated, the condition can result in permanent neurological damage or death.
Karthik Achari, a Chicago-based clinician, commented on the study. He noted that while the condition is rare, affecting only a small number of patients, it is serious. The medications may reduce appetite, leading to vitamin deficiencies.
Erin Palinski-Wade, a nutritionist, stressed adequate nutrition and hydration when using GLP-1 medications. She advised patients to ensure intake of protein, fiber, and fluids.
Persistent symptoms like vomiting or diarrhea should prompt medical consultation, as they could risk dehydration and kidney issues.
The study, based primarily on submitted reports, does not conclusively link the medications to the condition. Researchers called for further studies, urging patients not to stop their medication without consulting a physician.
Leave a Reply